VNA
STOK icon

Valley National Advisers’s Stoke Therapeutics STOK Stock Holding History

Valley National Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-750
Closed -$24K – 1074
2026
Q1 		$24K Hold
750
– – ﹤0.01% 484
2025
Q4 		$23K Hold
750
– – ﹤0.01% 490
2025
Q3 		$17K Hold
750
– – ﹤0.01% 491
2025
Q2 		$8K Hold
750
– – ﹤0.01% 611
2025
Q1 		$4K Hold
750
– – ﹤0.01% 667
2024
Q4 		$8K Buy
+750
New +$9.21K ﹤0.01% 580

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Valley National Advisers's STOK Position: Q2 2026 in Review

Valley National Advisers sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 750 shares — an estimated $24K sold.

Valley National Advisers first reported a position in STOK in Q4 2024 and held it in 6 quarters. The position peaked at $24K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Valley National Advisers reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Valley National Advisers sold 750 Stoke Therapeutics shares in Q2 2026, an estimated $24K.
  • Valley National Advisers first reported a position in Stoke Therapeutics in Q4 2024 and held it in 6 quarters.
  • Valley National Advisers's Stoke Therapeutics position peaked at $24K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.